A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Platinum-Doublet Chemotherapy or Immunotherapy in Subjects With Advanced Non-Small Cell Lung Cancer/Extensive-Disease Small Cell Lung Cancer
Latest Information Update: 22 May 2022
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Ipilimumab; Paclitaxel; Pegfilgrastim; Pemetrexed
- Indications Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Acronyms KEYNOTE-011
- Sponsors Merck Sharp & Dohme
- 28 Apr 2020 Status changed from active, no longer recruiting to completed.
- 09 Apr 2019 Planned primary completion date changed from 1 Jun 2018 to 30 Jun 2020.
- 09 Apr 2019 Planned End Date changed from 30 Jun 2019 to 30 Jun 2020.